+ T cell fate decisions. How CD8 + T cells integrate IL-2 signals in the development of functional memory is not well understood. Because IL-2 induces potent activation of the STAT5 transcription factor, we tested the role of STAT5 in CD8 + memory T cell differentiation and function using a model system in which STAT5 activity is inducibly abrogated upon CD8 + T cell activation. We report that STAT5 activity is broadly important for the expansion and effector function of all effector CTL subsets. After pathogen clearance, STAT5 was required for the survival of effector phenotype memory CTLs during the contraction phase. However, despite its role in supporting full primary CD8 + T cell expansion, and unlike IL-2, STAT5 activity is not required for the development of memory CD8 + T cells capable of robust secondary expansion upon rechallenge. Our findings highlight differential requirements for survival signals between primary and secondary effector CTL, and demonstrate that IL-2-dependent programming of memory CD8 + T cells capable of secondary expansion and secondary effector differentiation is largely STAT5 independent. The Journal of Immunology, 2013, 190: 3390-3398 . E nvironmental signals, including those from cytokines, play an essential role in effector and memory CD8 + T cell differentiation (1) . The common g-chain (g c ) family cytokine IL-2 has been shown to drive CD8 + T cell effector and memory differentiation (2) (3) (4) (5) . We and others have shown a role for IL-2 during the primary immune response in driving differentiation of effector CTL (2-4), as well programming of memory CD8 + T cells capable of robust recall responses (3, 5) . How CD8 + T cells integrate signals from cytokines to determine fate decisions is not fully understood. Specifically, how do cytokines, such as IL-2, induce signaling pathways that result in longlived memory CD8 + cells capable of protective recall responses? Several transcription factors, including T-box expressed in T cells (6) (7) (8) (9) (10) (11) , Eomesodermin (Eomes) (6, 8, 12, 13) , B lymphocyteinduced maturation protein (PRMD1/Blimp-1) (14) (15) (16) (17) (18) , and B cell lymphoma 6 protein (Bcl-6) (14, 19, 20) , have been shown to have crucial roles in CD8 + T cell effector differentiation and effector versus memory fate decisions. In the case of T-bet (6, (8) (9) (10) (11) and Blimp-1 (14, (16) (17) (18) , increased activity promotes a more differentiated terminal effector state in CD8 + T cells. In contrast, Eomes (6, 8, 12, 13) and 19, 20) are associated with establishment of long-lived memory CD8 + T cell populations. In the case of effector CD4 + T cell differentiation, connections between cytokines and transcriptional programs are relatively well described and in several lineages involve STAT proteins (21) . In contrast, the molecular connection between environmental signals such as cytokines received by CD8 + T cells during an immune response and the resulting transcriptional outcome driving differentiation toward terminal effector versus memory CD8 + T cell fate is less clear. The induction of transcription factors such as T-bet and Blimp-1 by cytokines appears to play a key role in this process (9, 22, 23) .
We have shown a crucial role for the cytokine IL-2 in the differentiation of effector and memory CD8 + T cells. IL-2 signals during the primary response to infection are critical in promoting the differentiation of effector and effector memory CTL (3). Moreover, IL-2 signals received by CTL during the primary response program memory CD8 + T cells capable of robust secondary responses (3, 5) and secondary effector differentiation (3) . We sought to determine the signaling pathways induced by IL-2 during a primary immune response that are involved in CD8 + T cell fate decisions and memory CD8 + T cell programming. The JAK3/STAT5, PI3K/Akt, and MAPK signaling pathways are potently activated by IL-2 (24) . Of these pathways, PI3K/Akt and MAPK are activated by a variety of other cytokine receptors, TCR ligation, and costimulatory signals (25) (26) (27) (28) during T cell activation. Other g c cytokines in addition to IL-2, such as IL-7 and IL-15, also activate JAK3/STAT5, but the timing, magnitude, and context of this signaling differ because of cytokine availability and differential regulation of the specific receptor subunits (29) . IL-2 potently activates STAT5 during the differentiation of effector CTL. Although IL-15 and IL-7 can also activate STAT5 during the effector CTL response, they play a dominant role in the maintenance of memory T cells after Ag clearance (29, 30) . Moreover, IL-15 and IL-7 signals are not required for the programming of memory CD8 + T cells (3, 31, 32) , as is the case with IL-2 (3, 5). IL-2 is an important catalyst for robust STAT5 activation during primary CTL responses, and we hypothesized that IL-2-mediated activation of STAT5 was a key step in the differentiation of highly functional CD8 + memory T cells.
Two isoforms of STAT5 exist, STAT5a and STAT5b, which have redundant functions in T cell homeostasis (33, 34) . Mice with deletion of both stat5a/b fail to develop T cells (35, 36) , demonstrating that STAT5 is essential during thymic selection. Recent reports examined the role of STAT5 in the survival of effector and memory CD8 + T cells after pathogen clearance (37, 38) . In the absence of STAT5, effector CD8 + T cells show reduced accumulation at the peak of the primary response to infection, possibly because of their inability to induce Bcl-2 via STAT5 in response to IL-7 and IL-15 (38) . Forced expression of a constitutively active form of STAT5 increased the numbers of effector CTL at the peak of the primary response to lymphocytic choriomeningitis virus (LCMV) and augmented survival of all CD8 + T cell subsets through contraction and memory (37) . These studies support a role for STAT5 signaling in effector and memory CD8 + T cell survival, mainly in the context of IL-15 and IL-7 signaling. However, high IL-2 levels potently drive STAT5 activation during the primary CTL response, and to date no studies have examined the role of STAT5 in differentially promoting effector and memory CTL subsets or in the programming of secondary CTL responses, two functions that have been described for IL-2 (3, 5) . In this study, we use a unique experimental system in which STAT5 deletion is selectively targeted to activated CTL in an otherwise normal immune environment.
To determine the contribution of STAT5 to CD8 + effector and memory T cell differentiation, we used a bone marrow (BM) chimera mouse model in which stat5a/stat5b are inducibly deleted upon CTL activation. We found that STAT5 was broadly important for all effector CD8 + T cell subsets during the primary response to acute infection, as well as the survival of effector phenotype CTL during contraction. After contraction, STAT5-independent memory CD8 + T cell populations were readily detectable, but whereas STAT5 was required for robust expansion and survival of primary effector CTL, STAT5-deficient memory CD8 + T cells mounted robust recall responses comparable with wild-type (WT) levels and underwent effective secondary effector CTL differentiation. Our findings highlight a differential requirement for survival signals mediated by STAT5 during primary and secondary CD8 + T cell responses. Moreover, our data suggest that IL-2-driven differentiation and programming of memory CD8 + T cells with robust recall potential is largely STAT5 independent. fl/fl (41) (supplied by L. Henighausen, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD) mouse colonies were maintained at the University of Utah (Salt Lake City, UT). All experiments were performed with the approval of the Institutional Animal Care and Use Committee at the University of Utah. LCMV strains Armstrong 53b and clone 13 were grown in BHK cells and titered in Vero cells as described previously (42) . Primary infection was at a dose of 2 3 10 5 PFU i.p. For secondary challenges, mice were given 2 3 10 6 PFU LCMV-Cl.13 i.v. or 2 3 10 5 PFU LCMV-Arm i.p. Recombinant Listeria monocytogenes expressing the LCMV GP [33] [34] [35] [36] [37] [38] [39] [40] [41] peptide (Lm-gp33) was propagated in BHI broth and agar plates as previously described (43) (44) (45) . Before infection, bacteria were grown to log phase and concentration determined by measuring the optical density at 600 nm (optical density of 1 = 1 3 10 9 CFU/ml). For secondary challenges, mice were injected i.v. with 1 3 10 4 CFU.
Materials and Methods

Mice and infections
Irradiation chimeras
Host B6.PL (Thy1.1 + ) mice were given a dose of 900 rad using the analytical x-ray irradiator in the mouse vivarium at the University of Utah. The next day, mice received 5 3 10 6 BM cells i.v. harvested from the femurs and tibias of Thy1.1 + or Thy1.2 + donor mice as indicated. BM cells were prepared by RBC lysis and depletion of CD3 + cells using biotinylated anti-CD3 Ab (eBioscience, San Diego, CA), anti-biotin magnetic beads (Miltenyi Biotec, Auburn, CA), and passage through magnetic column following manufacturer's guidelines (Miltenyi Biotec). After 8-10 wk, reconstitution within the CD8 + T cell compartment was determined using Abs to the congenic markers Thy1.1 and Thy1.2.
Cell suspensions and cell sorting
Splenocytes and lymph node cells were harvested at indicated time points postinfection and placed in single-cell suspension in RPMI 1640 with 10% FBS, L-glutamine, and penicillin/streptomycin before further analysis. Liver lymphocytes were harvested and subjected to collagenase digestion as previously described (46) . Cell sorting of CD8 + YFP + cells was performed using a FACS Aria II cell sorter (BD Biosciences) at the University of Utah FACS Core Facility, followed by immediate adoptive transfer by i.v. injection into the indicated secondary hosts.
Flow cytometry and analysis
Abs conjugated to fluorescent dyes were purchased from eBioscience (San Diego, CA), BioLegend (San Diego, CA), BD Biosciences (Mountain View, CA), or Santa Cruz Biotechnology (Santa Cruz, CA). Abs were specific for the following Ags: CD8, Thy1.1, Thy1.2, killer cell lectin-like receptor subfamily G member 1 (KLRG1), IL-7Ra, CD62L, T-bet, Eomes, Bcl-6, GzB, and STAT5-pY694. For cell-surface staining, single-cell suspensions were incubated with Abs in FACS buffer (PBS with 2% FBS and 0.02% sodium azide). For intracellular staining of T-bet and GzB, cells were permeabilized and stained using the BD Cytofix/Cytoperm kit and manufacturer's instructions (BD Biosciences). For intracellular staining of Eomes, cells were prefixed in 0.5% paraformaldehyde to preserve the YFP signal, washed twice, then fixed using Foxp3 Fix/Perm Buffer kit and manufacturer's instructions (eBioscience). To detect STAT5-pY694, we followed the BD Phosflow kit and manufacturer's protocol (BD Biosciences). H-2D b /GP [33] [34] [35] [36] [37] [38] [39] [40] [41] and H-2D b/ NP 396-404 tetramers were prepared as previously described (47, 48) . Multiparameter analysis of stained cells was performed using a FACSCanto II flow cytometer (BD Biosciences) and results were analyzed using FlowJo software (Tree Star, Ashland, OR).
Intracellular cytokine staining
Single-cell suspensions in RPMI 1640 containing 10% FBS, L-glutamine, and penicillin/streptomycin were incubated with 0.1 mM GP [33] [34] [35] [36] [37] [38] [39] [40] [41] or NP [396] [397] [398] [399] [400] [401] [402] [403] [404] peptides in the presence of GolgiPlug (BD Biosciences) for 4-5 h. Cells were stained with cell-surface Abs, fixed, and permeabilized using a kit (BD Biosciences), and stained with fluorescently labeled anti-cytokine Abs specific to IFN-g, TNF-a, and IL-2 (eBioscience).
CTL assays
We used a CTL assay as previously described (6) . EL-4 target cells were incubated with 0.1 mM GP 33-41 peptide for 2 h at 37˚C. Cells were washed and then incubated with sorted STAT5 WT or STAT5 conditional knockout (CKO) P14 CTLs for 2 h at CTL to target ratios ranging from 3:1 to 0.1:1. The percentage of Annexin V + target cells was determined by FACS using Annexin V-allophycocyanin apoptosis detection kit (eBioscience). Specific lysis was determined by comparison of killing of target cells without peptide loading. 
Real-time PCR
Results
STAT5 is required for accumulation of primary CTL during acute infection
To study the role of STAT5 signals in CD8 + T cell effector and memory differentiation, we created a mouse BM chimera model system in which stat5a and stat5b are deleted in activated CD8 + T cells, and the resulting STAT5-deficient CD8 + T cells are traceable by permanent expression of YFP (Fig. 1A) . BM was harvested from mice with the following genetic components: Cre recombinase driven by the GzB promoter (39) (GzB-Cre), RosaYFP reporter construct (40) , and the stat5a/b genes flanked by loxP sites (41) (stat5 fl/fl ), which we will subsequently refer to as "STAT5 CKO" BM. The donor BM was mixed 1:1 with WT B6.PL BM ("WT B6") and transplanted into irradiated B6.PL hosts. This set of chimeras will subsequently be referred to as STAT5 CKO chimeras. A second set of BM chimeras was made in an identical fashion, except the donor BM contained the stat5a/b genes without LoxP sites (stat5 wt/wt ) and will be referred to as STAT5 WT chimeras (Fig. 1A) . We distinguished between STAT5 (Thy1.2 + ) and B6.PL (Thy1.1 + ) donor-derived T cells over the course of infection based on differential expression of congenic Thy1 alleles. In this model system, activation of Cre activity upon CTL activation, driven by GzB induction, results in the deletion of LoxP-flanked stat5a/b as well as a LoxP-flanked stop codon preceding YFP under the control of the Rosa26 promoter. Because GzB expression is an early event after CTL activation (39), permanent YFP expression serves as an effective surrogate marker for Cre-mediated gene deletion during CTL differentiation and expansion. Importantly, the mixed BM chimera model system allows for the study of CTL-specific STAT5 activity without complications arising from differences in pathogen clearance.
Before infection, small numbers of YFP + cells could be detected among the STAT5 WT (∼5%) and at much lower levels among the STAT5 KO (∼0.5%) CD8 + T cells (Fig. 1B) . These cells were largely CD44 lo CD122
lo and CD62L hi , indicating that they did not arise through homeostatic proliferation and do not represent a preexisting memory phenotype population (Supplemental Fig. 1 ). Postinfection with LCMV-Armstrong, CD8 + T cell expansion was evident in both STAT5 WT and STAT5 CKO chimeras, and both groups of chimeras cleared the infection as expected (data not shown). A clearly distinguishable CD8 + YFP + population was seen in both STAT5 WT and STAT5 CKO chimeras on day 8 postinfection (Fig. 1B) . When gated on STAT5 WT or STAT5 CKO donor CD8 + T cells (Thy1.2 + ), .90% of KLRG1-expressing effector CTL also expressed YFP, confirming that activation of YFP and expression of the YFP reporter was highly efficient (Fig. 1C) genomic PCR and the expression of STAT5a mRNA by RT-PCR. FACS-sorted STAT5 WT YFP + CTL expressed ∼15-to 20-fold higher levels of STAT5a mRNA, whereas genomic PCR revealed a ∼15-fold decrease in stat5a/b genomic DNA, both numbers roughly consistent with the FACS sort purity (Supplemental Fig. 2) .
After LCMV infection, we observed a defect in the overall expansion of CD8 + YFP + effector CTLs in the spleen in the absence of STAT5. Whereas STAT5 WT chimeras displayed similar expansion of CD8 + T cells derived from either donor, STAT5 CKO chimeras displayed deficient expansion by CD8 + T cells derived from the STAT5 CKO donor (Fig. 1E) . By day 8 postinfection, the CD8 + T cell population in the spleens of STAT5 CKO chimeras was almost entirely derived from the WT donor (Fig. 1F) , indicating a decreased accumulation of STAT5 CKO CD8 + T cells at day 8 postinfection compared with WT.
We examined WT and STAT5 CKO CD8 + T cells for differences in antiapoptotic, prosurvival, or proapoptotic gene expression on day 8 postinfection with LCMV and found no significant differences in expression of the prosurvival genes Bcl-2 and Mcl-1, and no difference in expression of the proapoptotic gene Bim (Table I) . STAT5 WT CD8
+ T cells showed a modest but significant increase in expression of the prosurvival molecule B cell lymphoma extra large (Bcl-xL) over STAT5 CKO CD8 + T cells (Table I) Fig. 2A) , because of the overall loss in CD8 + T cells, the total number of STAT5 CKO Ag-specific CD8 + T cells was substantially lower than WT at the peak of the response in the spleen (Fig. 2B) . Because measuring total numbers does not take into account the change in frequency of donor CD8 + T cells seen between days 0 and 8 postinfection (Fig. 1D) , we normalized the CTL response in each chimera to the predicted response based on the ratio of donor WT to donor STAT5 WT or STAT5 CKO CD8 + T cells before infection. We found that the STAT5 CKO Ag-specific CD8 + T cell response was ∼4-fold lower than the WT response seen in STAT5 WT CTLs (Fig. 2C) . In all, the STAT5 WT YFP + CTL response was similar in magnitude to the response of WT donor CTL in the same host, as well as the WT control CTL in the STAT5 CKO chimeras (data not shown).
These differences were not due to inefficient deletion of STAT5, because Ag-specific YFP + STAT5 CKO CTLs displayed virtually no STAT5 phosphorylation at day 8 postinfection upon exposure to IL-2 (Fig. 2D) . Similar results were found at day 5 postinfection (data not shown), the earliest time point at which we were able to detect tetramer-binding CTL in the spleen. Although we cannot pinpoint in vivo STAT5 inactivation precisely, in vitro activation of CD8 + STAT5 CKO T cells resulted in undetectable STAT5 activity within 48 h of activation (data not shown). Therefore, we conclude that our model system results in rapid inhibition of STAT5 activity, and that STAT5 is an important survival signal for CD8 + T cells undergoing expansion during primary immune challenge. We cannot rule out the possibility that STAT5 provides key survival and/or differentiation signals in the first hours after activation.
STAT5 influences CTL function but does not drive CTL differentiation
To explore whether STAT5 influenced effector CTL differentiation, we examined the localization, expression of effector molecules, and function of effector CTLs in the absence of STAT5. Agspecific WT and STAT5 CKO CD8 + T cells were present at similar frequencies in the liver of LCMV-infected mice on day 8 postinfection (Fig. 3A) , demonstrating that CTL form and traffic to peripheral sites of infection even in the absence of STAT5. In addition, STAT5 CKO CD8 + T cells produced IFN-g and TNF-a at similar frequencies and levels upon peptide restimulation of splenocytes (Fig. 3B ) and liver lymphocytes (data not shown). STAT5 CKO tetramer + CD8 + T cells readily expressed similar (Fig. 3C ). In addition, STAT5 CKO CTL degranulated normally upon peptide restimulation, as measured by the surface expression of CD107a (LAMP-1) after peptide restimulation (data not shown). STAT5 CKO CTL also expressed similar levels of Ki-67 compared with STAT5 WT CTL, suggesting that defects in accumulation were not due to poor cell division, but rather poor survival (data not shown).
Modest differences in mRNA levels (Table I) were seen for two transcription factors, T-bet and Eomes, that are associated with effector CTL (9, 11) and effector to memory CD8 + T cell transition (8, 12) , respectively. However, protein expression levels of T-bet and EOMES were not changed in the absence of STAT5 (Fig. 3C) . Transcriptional control of CD8 + T cell terminal differentiation versus memory formation is mediated by the inverse activity of Blimp-1 and Bcl-6 (14). We saw a reduced level of Blimp-1 mRNA and an increased level of Bcl-6 mRNA in CD8 + T cells lacking STAT5 compared with WT (Table I) . Interestingly, STAT5 has been shown to inhibit follicular helper T cell differentiation in effector CD4 + T cells through increasing Blimp-1 expression and ultimately negatively regulating Bcl-6, which drives follicular helper T cell fate (49, 50) . When we examined protein levels of Bcl-6, we did not see differences (Fig. 3C) , but it remains possible that STAT5 impacts Blimp-1/Bcl-6 activity at early time points after activation, and thus may favor effector CTL differentiation in a manner similar to what is seen for CD4 + T cells.
To test effector function more directly, we compared target cell lysis of STAT5 WT and STAT5 CKO CD8 + T cells on day 8 postinfection. We found approximately a 2-fold decrease in killing on a per-cell basis in the absence of STAT5 (Fig. 3D ). This could be potentially explained by the lower levels of Prf1 mRNA expressed by STAT5 CKO CTL compared with WT CTL (Table I) and is consistent with a report that STAT5 binds the Prf1 promoter and drives Prf1 expression in CTL (4).
Overall, our data suggest that on a per-cell basis, STAT5 deficiency has a modestly adverse impact on CTL effector function. This is similar to the modest decrease in effector function seen in CTLs that do not receive IL-2 signals (3), and it is likely that IL-2-driven acquisition of effector function is mediated, at least to some degree, by STAT5. However, taking into account that STAT5 does not affect peripheral localization of effector CTLs and that STAT5 CKO CTLs express GzB, cytokines, transcription factors, and FasL equal to WT (Fig. 3, Table I ), we conclude that STAT5 plays only a modest role in the development of primary effector CTL function.
CTL differentiation is heterogeneous, including effector and memory precursor CD8 + T cell subsets that form part of the overall effector CTL pool. These two populations can be distinguished based on cell-surface expression of KLRG1 and IL-7Ra (9). We and others have shown that IL-2 signals drive differentiation of terminal effector phenotype CTLs during the primary response (2, 3). To determine whether IL-2-driven effector differentiation could be mediated by STAT5, we examined the differentiation of STAT5 CKO Ag-specific CD8 + T cells based on IL-7Ra and KLRG1 expression post LCMV infection. We found that the total numbers of STAT5 CKO IL-7Ra lo KLRG1 hi CD8 + T cells were decreased at the peak of the effector response and declined at nearly a 10-fold faster pace than STAT5 WT IL7Ra lo KLRG1 hi CD8 + T cells between days 8 and 40 postinfection (Fig. 4A, 4C ). Whereas CD8 + T cells activated in the absence of IL-2 signals generate normal numbers of memory precursor CTLs (3), STAT5 CKO memory precursor IL-7Ra hi KLRG1 lo CD8 + T cells were also reduced at effector time points and declined rapidly between days 8 and 40 postinfection (Fig. 4B, 4C) . We conclude that in contrast with IL-2, STAT5 does not selectively drive differentiation of effector phenotype CTLs and is instead important for the emergence of all CTL subsets through the peak of expansion. After clearance of pathogen, STAT5 signals are important for maintaining IL-7Ra lo KLRG1 hi phenotype CTLs through contraction and into the memory phase.
STAT5 signals are important for maintenance of tissue-residing memory CTLs after pathogen clearance
Memory CD8
+ T cell populations were detectable in the spleen in the absence of STAT5 post LCMV infection, although at lower numbers than WT (Fig. 5A) . Importantly, surviving memory cells did not express detectable STAT5 (Fig. 6A) , indicating that memory CTLs can emerge in the absence of STAT5, albeit at lower levels. We did not examine memory CD8 + T cell survival and homeostasis beyond 6 wk postinfection because of the known role of IL-15 and IL-7 in long-term memory T cell maintenance (30) . At early memory time points, the absence of STAT5 resulted in rapid loss of CD62L lo effector memory CTLs in the spleen (Fig.  5B) , and the preferential and specific decline of tissue-homing effector memory CTLs in the liver (Fig. 5C ). These findings are consistent with the role of IL-2 in effector memory CTL differentiation and suggest that IL-2-driven STAT5 activation is a key driver of effector memory CTL establishment (3, 5) . After pathogen clearance, STAT5 signaling is particularly important for ef- fector memory and tissue-residing memory CD8 + T cell survival (Fig. 5B, 5C ).
STAT5 CKO memory CTLs have robust recall capacity
Because IL-2 signals during primary CTL activation are required for the formation of memory CTLs capable of robust secondary responses (3, 5), we assessed the ability of STAT5 WT and STAT5 CKO memory CTLs to respond to rechallenge. Before rechallenge, we verified that Ag-specific memory CD8 + YFP + T cells from STAT5 CKO chimeras did not express detectable STAT5 (Fig. 6A) . Direct rechallenge of memory-phase BM chimeras is difficult to interpret due to the inability to distinguish between recall responses by YFP + memory CD8 + T cells and recruitment of YFP 2 memory or naive CD8 + T cells that subsequently express YFP. Therefore, we used an adoptive transfer strategy to determine recall capacity in the absence of STAT5. STAT5 WT or STAT5 CKO CD8 + YFP + memory CTLs were FACS purified from the spleens of mixed chimeras 6 wk after LCMV infection, analyzed for frequency of CD8 + tetramer + cells, and transferred into naive B6 hosts. Twenty-four hours after adoptive transfer, the naive B6 hosts were infected with LCMV clone 13 to induce recall responses by YFP + memory CD8 + T cells (Fig. 6B) . Similar rechallenges were done using LCMV Armstrong or recombinant Lm-gp33 as a secondary stimulus, with similar results (data not shown).
Ag-specific STAT5 WT and STAT5 CKO YFP + CD8 + T cells were clearly visible in the spleens of the infected hosts at day 5 after rechallenge (Fig. 6C ). In contrast with the primary response, STAT5 CKO memory CD8 + T cells expanded at levels similar to WT when rechallenged (Fig. 6C, 6D ). This is in striking contrast with the defective accumulation upon rechallenge of memory CD8 + T cells generated in the absence of IL-2 (3, 5) . As in the primary response, STAT5 CKO secondary CTLs expressed normal levels of GzB (Fig. 7A), effector cytokines (Fig. 7B) , and differentiation-associated transcription factors T-bet and Eomes (Fig.  7A ). When rechallenged with Lm-gp33, STAT5 CKO secondary CTLs trafficked to the liver normally (Fig. 7C ). There was a modest decrease in formation of secondary KLRG1
hi IL-7Ra lo phenotype CD8 + T cells in the absence of STAT5 (Fig. 7D ), but STAT5 CKO secondary CTLs expressed normal levels of Prf1 mRNA (Fig. 7E ), in contrast with the primary CTL response. In addition, STAT5 CKO secondary effector CTLs degranulated normally after restimulation, as measured by surface CD107a expression (data not shown). Our results indicate that STAT5 has little effect on secondary effector CTL differentiation. We conclude that IL-2-driven programming of memory CD8 + T cells capable of robust secondary expansion is largely STAT5 independent.
Discussion
Our results demonstrate a broad role for STAT5 signaling in the primary response to infection in promoting the accumulation of effector CTLs, and a more selective role for STAT5 in the survival of effector phenotype and establishment and survival of tissueresiding memory CD8 + T cells after pathogen clearance. Despite its role in promoting robust primary effector CTL responses, we make two novel observations. First, STAT5 is not required for IL-2-driven memory differentiation, reflecting the potential participation of other IL-2-dependent signaling pathways in this process. Second, the requirement for STAT5 activity in the primary and secondary CTL response is different, with secondary CTLs differentiating and expanding normally in the absence of STAT5. A study using direct infection of mice with conditional stat5 deletion driven by a type I IFN-responsive promoter showed that cell division of WT and STAT5-deficient CD8 + T cells on day 8 postinfection was the same (38) . Our observations of poor primary expansion in the absence of STAT5 also likely reflect poor survival, and we propose that the survival of secondary effector CTLs is controlled by distinct mechanisms. In addition, the absence of IL-2 signaling during the in vivo response to acute infection impacts survival whereas having little effect on cell division (5) .
Consistent with reduced survival in the absence of STAT5, we observed reduced expression of the prosurvival molecule Bcl-xL in STAT5 CKO CD8 + T cells at day 8, similar to its expression in the absence of IL-2 signals (3). It is known that STAT proteins, including STAT5, can induce Bcl-xL in several cell types (51) . Although it is possible that IL-2-induced STAT5 could promote survival of CD8 + T cells during the primary response through induction of Bcl-xL, T cells lacking Bcl-xL (all isoforms) were able to mount normal responses to Listeria monocytogenes infection (52) . Thus, the functional impact of differences in Bcl-xL mRNA levels during primary CTL expansion in the absence of STAT5 is not clear.
We find that STAT5 signals are broadly important for all subsets of effector CTL cell during primary expansion, suggesting that STAT5 does not drive CD8 + T cell fate decisions during the primary response. This is in contrast with the specific role of IL-2 in preferentially promoting the differentiation of effector phenotype CTL (3). Another g c family member, IL-21, is able to activate STAT5, although to a lesser degree than IL-2 (53), and has recently been identified as being important in CD8 + T cell differentiation in the context of chronic (54) (55) (56) and acute infection (57) . Additional STAT5 activation during the primary response is likely stimulated by IL-7 and IL-15, and we have found that the combined absence of IL-2 and IL-15 enhances the defect in terminal effector CTL differentiation during the primary response (3). Our results suggest that STAT5 may have graded effects on CTL differentiation. Although some loss of STAT5 activation induced by IL-2 could influence effector phenotype CTL formation, STAT5 activation induced by other cytokines may be sufficient for the differentiation of memory precursor CTL. Complete loss of STAT5, however, results in a defect in both terminal effector phenotype and memory precursor CTL.
IL-15 selectively promotes survival of effector phenotype CTL after viral clearance. Although IL-15 induces STAT5 signaling, we observed a switch from a broad requirement for STAT5 during expansion to a more selective requirement for its activity in the maintenance of effector phenotype and long-lived effector memory CD8 + T cells during contraction and into the memory phase. This could be because of different levels of STAT5 activation induced by IL-15 and IL-7 (58). IL-7 also efficiently activates STAT5, and it has roles in both the generation and survival of memory CTLs (32) . Alternatively, another report has shown that effector phenotype CD8 + T cells are more dependent on STAT5 signals for survival during contraction (37, 38) . Collectively, these reports and ours emphasize that for different CD8 + T cells subsets, there appears to be differential usage of and access to common signaling cascades induced by g c cytokines at distinct stages of differentiation.
Importantly, we observed the emergence of a STAT5-deficient memory CD8
+ T cell population 6 wk postinfection, albeit at much lower levels than what was seen for WT. This brings to question the survival signals that are used in the absence of STAT5 and to what degree these signals are used under normal conditions. A recent report suggests that STAT5-independent survival signals could be used in the formation of memory CD8 + T cell populations (58) , but the nature of those signals remains unknown. Another recent study showed that memory precursor CTLs were able to activate PI3K/Akt in an IL-15-dependent manner more efficiently than effector phenotype CTLs (37) . However, hyperactivation of this pathway was detrimental to long-term survival of memory CD8 + T cells. Despite being a key mediator of IL-2 signals, we found that STAT5 was dispensable for the ability of memory CD8 + T cells to mount robust secondary responses and undergo secondary effector CTL differentiation. This highlights a different requirement for STAT5 during primary and secondary CD8 + T cell responses, because STAT5-deficient primary responses were significantly reduced compared with WT. Moreover, this is in striking contrast with what was seen for memory CD8 + T cells generated in the absence of IL-2 signals, which failed to mount successful recall responses and failed to differentiate into secondary effector CTLs (3, 5) . Thus, the mechanism by which IL-2 signals during the primary response program memory CD8 + T cells is independent of STAT5 and remains to be defined.
Alternative candidate pathways induced by IL-2 that could play a role in memory CTL differentiation include STAT3 and PI3K/ Akt. STAT3 signals are also induced by IL-2 (53), and a role for STAT3 in persistence of memory precursor CTLs in mice (57) and CD8
+ central memory T cell formation in humans (59) has been suggested. Like STAT5, STAT3 is activated by a variety of other cytokines, such as IL-21 and IL-6 (53, 60), and it is unclear what proportion of STAT3 activity during the primary CTL response is IL-2 dependent. The phenotype of STAT3-deficient and IL-2Ra-deficient CD8 + T cells do not align, because IL-2 is important for terminal effector CTL (3), whereas STAT3 appears to be important for memory precursor phenotype CD8 + T cells (57) .
A more likely candidate is IL-2-dependent PI3K/Akt activation. Although this signaling pathway is induced in CD8 + T cells by a variety of sources, the additive effects of multiple signals, including IL-2, in the induction of PI3K/Akt activation for memory CD8 + T cell differentiation could be important. Moreover, several recent reports have suggested that the kinase mammalian target of rapamycin, which is downstream of PI3K/Akt activation, is a key regulator of effector and memory CTL fate decisions and survival (61) (62) (63) . Therefore, a likely future hypothesis is that IL-2 mediates its effects on the programming of secondary effector CTL responses, at least in part, through PI3K/Akt activation. 
